Clinical trials: Iron
Atherosclerotic Carotid Disease, Atheroma
Effects Of Atorvastatin On Macrophage Activity And Plaque Inflammation Using Magnetic Resonance Imaging
A new way of scanning narrowing in the arteries (main blood vessels) caused by fatty deposits known as plaques has been developed. Heart attacks and strokes occur when plaques become inflamed, depending on the artery affected.
- Conditions
- Atherosclerotic Carotid Disease, Atheroma, Atherosclerosis
- Trial name
- NCT00368589
- Testing
- atorvastatin
- Where
- United Kingdom
- Volunteers
- 47 people
- Sponsor
- GlaxoSmithKline
Anemia, Skin Condition
The Efficacy of Minayo Iron-rich Nutritional Gummies on Female Anemia, Skin Condition and Qi-blood Deficiency Syndrome
The goal of this randomized, double-blind, placebo controlled study is to learn about the efficacy of Minayo Iron-rich Nutritional Gummies on females who are aged 18-45 and suffer nutritional Anemia, skin condition and Qi-blood…
- Conditions
- Anemia, Skin Condition, Qi-blood Deficiency Syndrome
- Trial name
- NCT06869824
- Testing
- Minayo Iron-rich Nutritional Gummies, Common Gummies
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Hangzhou Agile Groups Network Technology Co., Ltd.
Iron Overload
Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload
The purpose of this study is to investigate the effects of iron chelation using deferasirox in patients who show signs of iron overload after an allogeneic stem cell transplantation The iron overload must be due to blood…
- Trial name
- NCT00654589
- Testing
- Deferasirox
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- Novartis Pharmaceuticals
Iron Deficiency Anemia (IDA)
Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia
The primary objective of this study is to compare the total costs to sites and payers of administering IV iron over the 30-day observation period for subjects with IDA who receive Ferric Carboxymaltose (FCM) relative to those who…
- Trial name
- NCT01984554
- Where
- United States
- Volunteers
- 551 people
- Sponsor
- American Regent, Inc.
Iron Deficiency Anaemia, Chronic Kidney Disease
Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
Phase IIIb study to evaluate the long-term efficacy of ferric carboxymaltose (FCM) (using targeted ferritin levels to determine dosing) or oral iron in non-dialysis-dependent chronic kidney disease (NDD-CKD) subjects with iron…
- Trial name
- FIND-CKD (NCT00994318)
- Testing
- FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate)
- Where
- 19 sites in United States, Australia and 17 more
- Volunteers
- 626 people
- Sponsor
- Vifor Pharma
Transfusional Hemosiderosis
Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox
This study will observe patients with transfusional hemosiderosis treated with deferasirox in actual practice setting.
- Trial name
- NCT01394029
- Testing
- deferasirox
- Where
- 10 sites in Egypt, Jordan and 2 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Iron Deficiency Anemia
Pharmacokinetics, Pharmacodynamics and Safety Study of Z-213 to Iron Deficiency Anemia
The safety, tolerability, pharmacokinetics and pharmacodynamics of Z-213 will be investigated in patients with iron-deficiency anemia after administration of a single dose (100 mg, 500 mg, 800 mg or 1,000 mg iron).
- Trial name
- NCT02170311
- Testing
- Z-213
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- Zeria Pharmaceutical
Hereditary Hemochromatosis
A Study to Evaluate BBI-001 in Hereditary Haemochromatosis (HH) Patients and Iron Deficient Volunteers
This is a first in human, double-blind, randomized, placebo-controlled, two-arm crossover study evaluating the safety, tolerability and PD of ascending dose levels of BBI-001 after: a single administration in iron deficient male…
- Trial name
- NCT05238207
- Testing
- BBI-001, Original Fibre Metamucil
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bond Biosciences
Diagnostic
Study of the Prevalence of Iron Deficiency in Patients With Scheduled Major Surgery (CARENFER PBM)
Many patients who are candidates for scheduled major surgery have a pre-operative iron deficiency which is poorly diagnosed. The management of per-operative iron deficiency is a part of the concept of the "Patient Blood…
- Trial name
- CARENFER-PBM (NCT04800042)
- Testing
- Diagnostic test
- Volunteers
- 1,700 people
- Sponsor
- VIFORFRANCE
Anemia
Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis Patients
The study will evaluate the safety and efficacy of a new intravenously administered iron drug to treat anemia in patients on hemodialysis.
- Trial name
- NCT00233597
- Testing
- ferumoxytol or oral iron
- Where
- 50 sites in United States
- Volunteers
- 230 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Beta-thalassemia Major, Hemosiderosis
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
To allow patients treated with deferasirox in the core study to continue iron chelation therapy for 2 years or until the drug became locally commercially available.
- Conditions
- Beta-thalassemia Major, Hemosiderosis, Iron Overload, Rare Anemia
- Trial name
- ESCALATOR (NCT00171301)
- Testing
- Deferasirox
- Where
- 5 sites in Egypt, Lebanon and 3 more
- Volunteers
- 233 people
- Sponsor
- Novartis Pharmaceuticals
Transfusional Iron Overload, Beta-thalassemia
Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload
The purpose of this research study is to study the safety of increasing doses of FBS0701, and to see how quickly the study medication is absorbed and how quickly it disappears from the bloodstream.
- Trial name
- NCT01039636
- Testing
- FBS0701
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 20 people
- Sponsor
- FerroKin BioSciences, Inc.
Iron Deficiency Anemia
Clinical Study of Z-213 in Subjects With Iron-deficiency Anemia
To confirm the safety and efficacy of Z-213 until 12 weeks after start of Z-213 administration in patients with iron deficiency Anemia
- Trial name
- NCT02828319
- Testing
- Z-213
- Where
- Japan
- Volunteers
- 39 people
- Sponsor
- Zeria Pharmaceutical
Transfusional Hemosiderosis
Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food
This single-arm, open-label, multi-center study enrolled 65 patients from approximately 20 centers. All patients who met the study criteria and were taking, beginning or resuming treatment with Deferasirox were allowed.
- Trial name
- NCT00845871
- Testing
- deferasirox:
- Where
- 23 sites in United States
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Inflammatory Bowel Disease, Anemia
FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR
The purpose of this study is to determine how safe, tolerable and effective the new standardised dosage regimen of FERINJECT® infusions is, compared with a well established intravenous iron treatment.
- Conditions
- Inflammatory Bowel Disease, Anemia, Iron Deficiency, Iron-Deficiency Anemia
- Trial name
- FER-IBD-COR (NCT00810030)
- Testing
- Ferric carboxymaltose, Iron Sucrose
- Where
- Austria
- Volunteers
- 484 people
- Sponsor
- Vifor Pharma
Iron Deficiency Anemia
To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency Anaemia
The primary objective is to demonstrate the efficacy of ferric carboxymaltose (FCM) given in a simple dosing regimen in correcting iron deficiency anaemia (IDA), by demonstrating non-inferiority to treatment with the currently…
- Trial name
- NCT03591406
- Testing
- Ferric carboxymaltose, Iron sucrose
- Where
- China
- Volunteers
- 371 people
- Sponsor
- Vifor (International) Inc.
Iron Overload, Sickle Cell Disease
Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias
This research is being done so that we can look at the safety and efficacy of deferiprone in people with sickle cell disease or other anemias. Deferiprone is a drug that removes iron from the body.
- Conditions
- Iron Overload, Sickle Cell Disease, Other Anemias
- Trial name
- FIRST (NCT02041299)
- Testing
- Deferiprone, Deferoxamine
- Where
- 33 sites in United States, Brazil and 6 more
- Volunteers
- 230 people
- Sponsor
- ApoPharma
Iron Deficiency Anemia
A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized Trial to Evaluate Efficacy & Safety in Anemia Subjects
To evaluate the efficacy and safety of 12 weeks treatment with Ferrous (II) Glycine Sulphate Complex in comparison to Polyferose capsules in Chinese subjects with manifest Iron Deficiency Anemia.
- Trial name
- NCT01425463
- Testing
- Ferrous (II) Glycine Sulphate Complex, Polyferose
- Where
- 15 sites in China
- Volunteers
- 256 people
- Sponsor
- Sanol GmbH
Infant Development
Comparison of Growth and Tolerance of Healthy Term Infants Fed Iron-Fortified Infant Formulas
A 4 month growth monitoring study of healthy term infants fed iron fortified infant formula. Infants will be fed ad-libitum for 16 weeks and growth will be evaluated in terms of weight gain over the 16 weeks.
- Trial name
- NCT05947084
- Testing
- Infant Formula
- Where
- 29 sites in United States
- Volunteers
- 518 people, healthy volunteers welcome
- Sponsor
- Aussie Bubs, Inc.
Chronic Iron Overload Due to Transfusion-dependant Anemias
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Assessed the new film-coated tablet formulation to the currently approved dispersible tablet formulation with regards to overall safety, Gastrointestinal (GI) tolerability, palatability, satisfaction and compliance
- Trial name
- NCT02125877
- Testing
- Deferasirox dispersible tablet, Defearisox film-coated tablet
- Where
- 51 sites in United States, Argentina and 14 more
- Volunteers
- 173 people
- Sponsor
- Novartis Pharmaceuticals